UK advisory agency recommends treatment with Alecensa (alectinib) for ALK+ non small cell lung cancer.-Roche.
The UK Medicines and Healthcare products Regulatory Agency has issued a positive Scientific Opinion allowing use of Alecensa (alectinib), from Roche, on the scheme for first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), while it is being assessed for marketing authorisation by European regulators.
Data from the phase III ALEX study showed that treatment naive patients taking alectinib had significantly prolonged progression free survival when compared with the current standard of care, crizotinib, with the risk of progression/death cut by 53 percent.
Comment: Alecensa was approved for use in the EU in February 2017 to treat adults with ALK+ non-small cell lung cancer who have previously been treated with crizotinib.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins